Overview

Efficacy, Tolerability, and Safety Study of DFN-15

Status:
Completed
Trial end date:
2019-05-01
Target enrollment:
Participant gender:
Summary
Efficacy, Tolerability, and Safety of DFN-15 in episodic migraine with or without aura, being conducted at multiple centers in the United States.
Phase:
Phase 3
Details
Lead Sponsor:
Dr. Reddy's Laboratories Limited
Treatments:
Celecoxib